EBV infection accelerates this process through LMP1 and EBNA2 mediated EMT induction, tumor protein 53 (TP53) dysregulation, activation of NF-κB signaling, and remodeling of the immune microenvironment, thereby promoting undifferentiated and treatment-resistant phenotypes. Here, TP53 is linked to Epstein-Barr virus infection.